# Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

> **NCT00065130** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 27 (actual)

## Conditions studied

- Diabetes
- Gestational Diabetes

## Interventions

- **DRUG:** human insulin
- **DRUG:** insulin NPH
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT00065130
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2016-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065130, "Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00065130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*